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 Retinitis pigmentosa (RP) is a group of hereditary reti-
nal diseases characterized by night blindness and progressive
loss of the visual field. It has a prevalence of about 1 in 4000
[1]. RP was the major cause of visual impairment among per-
sons who entered 29 rehabilitation centers in Japan, account-
ing for 25% of these cases [2]. RP is a disease with consider-
able genetic heterogeneity; it is transmitted as an autosomal
dominant, autosomal recessive, X-linked, or rare mitochon-
drial form. Moreover, digenic or syndromic forms of RP com-
plicate inheritance patterns [3,4]. The frequency of the inher-
ited type has been estimated as follows: 19% dominant, 65%
recessive or isolated, 8% X-linked, and 8% undetermined in
Maine in the United States [5]; 16.9% dominant, 25.2% re-
cessive, 1.6% X-linked, and 56.3% simplex in a study of Japa-
nese RP patients [6].
So far, positional cloning and candidate gene screening
have identified at least 36 loci responsible for RP [3] (for the
latest summary, see the RetNet page). Of the genes known to
cause autosomal dominant RP (adRP) in the United States and
Canada, mutations in a rhodopsin (RHO) gene were most fre-
quently observed, accounting for 24-29% of cases [7-9]. Since
RHO was identified as an RP-causing gene [10], a number of
mutations have been found at a variety of sites on the RHO
locus [1,7-9] (for the latest summary, see RHO). Most rhodop-
sin mutations cause adRP, whereas a few have been reported
to cause autosomal recessive RP (arRP) [11,12] or congenital
stationary night blindness [13-15]. In a total of 85 Japanese
adRP patients, the following five causative mutations in RHO
have been reported: Asn15Ser [16], Thr17Met [17], Gly106Arg
[18], Glu181Lys [19], Pro347Leu [17]. The rate of RHO mu-
tations in Japanese (5/85, 5.9%) is lower than that in the United
States, suggesting a race-dependent mutation rate [20].
A single-stranded conformation polymorphism method
targeting the coding regions has been frequently used for the
first screening of mutations [7-9,11], but this method intrinsi-
cally includes the possibility of missing mutations. Mutations
in a promoter region or introns may also be responsible for
arRP by affecting the levels of expression of RHO [13]. These
problems with mutation screening can be resolved by sequenc-
ing the entire region of the RHO locus. Furthermore, full se-
quencing provides information about single nucleotide poly-
morphism (SNPs) and haplotypes that could affect the expres-
sion levels of the gene. Promoter haplotype combinations have
been shown to affect the biological and therapeutic pheno-
types by altering the expression of the gene for β2-adrenergic
receptor [21]. This led us to hypothesize that RHO promoter
haplotypes are associated with susceptibility to RP via a mecha-
nism that changes the levels of expression of RHO. A search
for RP-related SNPs in RHO was carried out [22], but there
has been no report on the haplotype structure of RHO to date.
©2007 Molecular Vision
Mutation screening and haplotype analysis of the rhodopsin gene
locus in Japanese patients with retinitis pigmentosa
Yuichiro Ando,1,2 Masayuki Ohmori,1,2 Hideki Ohtake,1 Kuniyo Ohtoko,1 Shigeru Toyama,1 Ron Usami,2 Aya
O’hira,3 Hiromi Hata,3 Kenji Yanashima,3 Seishi Kato1
1Department of Rehabilitation Engineering, Research Institute, National Rehabilitation Center for Persons with Disabilities; 2De-
partment of Applied Chemistry, Graduate School of Engineering, Toyo University; 3Department of Ophthalmology, Hospital, Na-
tional Rehabilitation Center for Persons with Disabilities, Saitama, Japan
Purpose: To identify nucleotide sequence variations in the rhodopsin (RHO) gene of Japanese patients with retinitis
pigmentosa (RP) in order to search for mutations or haplotypes responsible for RP.
Methods: The entire region of RHO locus including a promoter region and introns was sequenced using blood-derived
genomic DNA samples donated by 68 patients with RP and 68 control subjects.
Results: We found 39 single nucleotide substitutions including 17 rare substitutions of less than 1% in frequency, one
insertion/deletion polymorphism, and one CA-repeat polymorphism in a 7.8 kbp region spanning the promoter, five
exons, and four introns of the RHO gene locus. There were no affected subjects with amino acid substitutions in RHO, and
there was 1 control subject with a novel substitution (Ala42Thr) who had no symptoms of RP. Fine analysis of single
nucleotide polymorphism (SNPs) revealed eight haplotype structures of the Japanese RHO locus. There was no signifi-
cant difference between RP patients and controls in terms of haplotype frequency.
Conclusions: No mutation causing an amino acid substitution of RHO was observed in 68 Japanese patients with RP, but
1 control subject did have a novel amino acid substitution. The Japanese RHO locus is comprised of eight major haplotypes.
The RP-associated haplotype was not identified. The haplotype-tagging SNPs identified in this study will be useful as
markers for the linkage-based screening of RP patients.
Correspondence to: Seishi Kato, Department of Rehabilitation Engi-
neering, Research Institute, National Rehabilitation Center for Per-
sons with Disabilities, 4-1 Namiki, Tokorozawa, Saitama 359-8555,
Japan; Phone: 81-4-2995-3100; FAX: 81-4-2995-3132; email:
seishi@rehab.go.jp
1038In the present study, we determined the full sequence of
the RHO locus, including the promoter regions and introns, in
order to search for RP-associated mutations and/or haplotypes
in the RHO loci of RP patients who visited the low-vision
clinic at our center.
METHODS
Subjects:  We studied 68 unrelated RP patients who visited
the low-vision clinic at our center. RP subjects were selected
on the basis of clinical findings, patient history, and family
history. Of these 68 patients, 26 had a family history, 27 had
no family history, and 15 had an unknown family history. Table
1 shows the detailed information on the 26 subjects with a
family history. Five of these patients had an affected parent
with RP or night blindness, and the patient designated as RP048
reported having an affected sibling whose son suffers from
RP. Thus, these six cases were diagnosed as adRP. Seven pa-
tients with grandparents or cousins with RP or night blindness
could have suffered from adRP. RP051 and RP062 reported a
family history of consanguineous marriage. Control samples
were obtained from students at the college affiliated with our
center and from members of our staff of the center, all of whom
declared having neither a personal history nor a family his-
tory of night blindness or unexplained visual loss. The study
was approved by the Human Genome-Ethics Committee of
the National Rehabilitation Center for Persons with Disabili-
ties and was performed in accordance with the Declaration of
Helsinki. Informed consent was obtained from all subjects
involved in this study.
DNA sample preparation:  Genomic DNA was isolated
from venous blood using a PUREGENE DNA purification Kit
(Gentra Systems, Minneapolis, MN). A sample for DNA se-
quencing was prepared by polymerase chain reaction (PCR)
using genomic DNA as a template. The genomic sequence of
the RHO locus (NT_005612.15) was retrieved from NCBI
database (Build 36.1). Nucleotide A of the initiation codon of
RHO was defined as Position 1. The primer sequences for PCR
amplification are listed in Table 2. The first PCR amplifica-
tion was performed in order to obtain two amplicons, A1 (con-
taining RHO exons and introns) and A2 (containing the pro-
moter region of RHO). Two hundred nanograms of genomic
DNA were amplified with Taq polymerase (TaKaRa Ex Taq®
Takara Bio Inc., Shiga, Japan) in a 50 µl reaction volume for
30 cycles under conditions of heating for 30 s at 96 °C, an-
nealing for 30 s at 63 °C, and extension for 2 min at 72 °C.
The second PCR amplification using amplicon A1 as a tem-
plate produced 4 amplicons (A3, A4, A5, A6).
Sequencing:  PCR products were sequenced bi-
directionally with a BigDye® Terminator Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA) using the primers
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TABLE 1. INFORMATION ON RETINITIS PIGMENTOSA PATIENTS WITH A FAMILY HISTORY
                                        Number
                             Number       of
           Patient             of      affected                                   Type of
 Number     ID       Sex    siblings   siblings    Other affected relatives      inheritance
-------   -------   -----   --------   --------  ----------------------------  -------------
   1       RP005      F        6          2      Mother(RP)                      ad
   2       RP008      F        7          2
   3       RP009      F        4          2      Grandmother(NB)                 ad(?)
   4       RP010      F        4          3
   5       RP016      F        8          3      Grandmother(RP?)                ad(?)
   6       RP017      F        5          2
   7       RP020      F        3          1      Cousin(central vision loss)     ad(?)
   8       RP021      M        3          2
   9       RP022      M        3          1      Grandfather(RP?)                ad(?)
  10       RP023      M        7          2
  11       RP024      M        2          2      Grandmother(RP?)                ad(?)
  12       RP029      M        3          2      Mother(NB), cousin(RP)          ad
  13       RP034      F        5          1      Father(NB), cousin(RP?)         ad
  14       RP035      M        3          1      Father(RP)                      ad
  15       RP036      F        8          5      Distant relative(RP?)           ad(?)
  16       RP037      F        3          1      Mother(RP)                      ad
  17       RP038      F        4          1      Cousin(RP)                      ad(?)
  18       RP039      M        2          2
  19       RP044      F        6          2
  20       RP045      M       10          4
  21       RP048      M        4          3      Affected sib’s son(RP)          ad
  22       RP051      F        2          2      Consanguineous marriage         ar
  23       RP061      M        4          2
  24       RP062      M        4          2      Consanguineous marriage         ar
  25       RP063      M        6          3
  26       RP064      F        7          3
Of 68 unrelated RP patients who visited the low-vision clinic at our center, 26 had a family history. Sex: Male (M), Female (F). Siblings and
affected siblings include the proband. NB indicates night blindness. Inheritance type: ad indicates autosomal dominant; ar indicates autosomal
recessive.
1039listed in Table 3. Sequencing reaction products were run on
an automated capillary sequencer (Applied Biosystems 3130xl
Genetic Analyzer, Applied Biosystems, Foster City, CA).
Haplotype analysis:  Haplotypes were estimated from
unphased genotypes using Clark’s algorithm [23] and the ex-
pectation-maximization (EM) algorithm [24]. Phylogenetic
analysis was carried out with the minimum spanning network
(MSN) algorithm [25]. The Arlequin program (Schneider,
Roessli, Excoffier, Arlequin version 2.000: A software for
population genetics data analysis, Geneva, Switzerland) was
used for the analysis using the EM algorithm and the MSN
algorithm.
RESULTS
Sequence variations:  Table 4 shows the sequence variations
obtained in this study. We identified a total of 41 sequence
variations consisting of 39 single nucleotide substitutions, one
insertion/deletion polymorphism (Indel, SV15), and one CA-
repeat polymorphism (SV16) in a total of 272 chromosomes
from 68 RP patients and 68 controls. Of 39 single nucleotide
substitutions, 25 sites were novel ones not registered in the
dbSNP database (National Center of Biotechnology Informa-
tion). This study did not find four substitutions (rs2855553,
rs2855556, rs2625964, rs2625969) registered in the dbSNP,
which seem to be rare among Japanese. Rare substitutions with
less than 1% minor allele frequency (MAF) occurred at 17
sites, nine of which were observed only in the RP patients and
six only in the controls.
Twenty substitutions with a MAF of greater than 1%
showed linkage disequilibrium (LD) between pairs, and these
substitutions were designated as SNP01 to SNP20. These SNPs
were consistent with the Hardy-Weinberg equilibrium (data
not shown). SV14 and SV27 exhibited 1.5% of the MAF, but
were excluded from the SNPs due to the absence of LD pairs.
Most SNPs with a MAF of greater than 10% were registered
in the dbSNP, with the exception of SNP11. Nine SNPs were
registered in a database of Japanese single nucleotide poly-
morphisms (JSNP) and the MAF values of these substitutions
were similar to each other at each site, except in the case of
SNP20. The differences between RP patient and control MAFs
were small, except in the case of SNP20. The MAF at SNP20
was 8.8% among RP patients and 19.9% among controls, re-
spectively. However, the mean MAF of all subjects at SNP20
was 14.4%, which is similar to the value described in the JSNP
database, i.e., 15.1% (1488 chromosomes).
Four rare single nucleotide substitutions were observed
in the coding region. Three substitutions (SV07, SV08, and
SV27) were synonymous. On the other hand, SV06 observed
in 1 control led to an amino acid substitution (Ala42Thr). SV03
was observed in the promoter region of one RP patient, and it
was located at position -503 upstream of the transcription start
site [26].
Intron 1 was found to contain an Indel of 10bp (SV15)
followed by a CA-repeat polymorphism (SV16,
(CA)nA(CA)m, n=12-14, m=15-27). The precise number of
repeats was not determined due to degeneration of sequences.
Haplotypes:  Haplotypes of the RHO locus were estimated
on the basis of 20 SNPs of 272 chromosomes obtained from
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TABLE 2. POLYMERASE CHAIN REACTION PRIMERS USED FOR AMPLIFY-
ING THE RHODOPSIN GENE LOCUS
Amplicon   Primer   Position           Sequence (5'->3')
--------   ------   --------   ----------------------------------------
   A1       A1F       -297     aaggccgcctcggCCTGGATCCTGAGTACCTCTCCTC
            A1R       6605     aagcggccgcTTTTCCCATTCCCAGGACTGCCTCCTCCAC
   A2       A2F      -1260     CAGTCATCTGCCCCCAAGGC
            A2R        142     TCAGCAGAAACATGTAGGCG
   A3       A1F       -297     aaggccgcctcggCCTGGATCCTGAGTACCTCTCCTC
            A3R       2402     CCTGGAACCAGACACTACTG
   A4       A4F       1951     GCTCTCCTCAGCGTGTGGTC
            A4R       4669     GCTGTGTCACCCGTGACATTTCAT
   A5       A5F       3735     CATGCATCTGCGGCTCCTGCTC
            A5R       6010     CTTCCAGAGGCTGAGAGAAAGGCC
   A6       A6F       5085     GAACGAAGTCACATAGGCTCC
            A1R       6605     aagcggccgcTTTTCCCATTCCCAGGACTGCCTCCTCCAC
Position 1 corresponds to the nucleotide A of the initiation codon of
the RHO gene. Lower letters represent an artificial sequence added
for cloning the polymerase chain reaction products.
TABLE 3. PRIMERS USED FOR SEQUENCING
Primer    Position      Sequence (5'-3')
-------   --------   ------------------------
Forward
 SF01      -926      CTAGCGTTCAAGACCCATTAC
 SF02      -452      GAGAGACTGGGAGAATAAACC
 SF03       153      CTTCCCCATCAACTTCCTCACG
 SF04       592      TGCGCTTGTCTAATTTCACAGC
 SF05      1053      GGAAAACAGATGGGGTGCTGC
 SF06      1476      CTTTCACTGTTAGGAATGTCC
 SF07      1951      GCTCTCCTCAGCGTGTGGTC
 SF08      2383      CAGTAGTGTCTGGTTCCAGG
 SF09      2860      CCTCCTCAGTCTTGCTAGGGTC
 SF10      3289      GGTGTCATCTGGTAACGCAG
 SF11      3735      CATGCATCTGCGGCTCCTGCTC
 SF12      4144      TGGCAGCAGTCTTGGGTCAGC
 SF13      4616      ACAGAACACCCTTGGCACACAGAG
 SF14      5085      GAACGAAGTCACATAGGCTCC
 SF15      5360      GATGGATGCAGGAAGGAATGGAGG
 SF16      5548      CTGAGAAGACCAAAAGAGGTG
 SF17      5987      GGCCTTTCTCTCAGCCTCTGGAAG
 SF18      6444      GGGTTTTGTTGCTTTCACACTC
Reverse
 SR01      -775      GTGGCTGTGAGGTTGTGGAGAC
 SR02      -284      ACTCAGGATCCAGGAAAAGG
 SR03       174      CGTGAGGAAGTTGATGGGGAAG
 SR04       613      GCTGTGAAATTAGACAAGCGCA
 SR05      1073      GCAGCACCCCATCTGTTTTCC
 SR06      1496      GGACATTCCTAACAGTGAAAG
 SR07      1970      GACCACACGCTGAGGAGAGC
  SR08     2402      CCTGGAACCAGACACTACTG
  SR09     2881      GACCCTAGCAAGACTGAGGAGG
  SR10     3308      CTGCGTTACCAGATGACACC
  SR11     3756      GAGCAGGAGCCGCAGATGCATG
  SR12     4204      GCCAGGAATCTGCATTTCTCAC
  SR13     4669      GCTGTGTCACCCGTGACATTTCAT
  SR14     5105      GGAGCCTATGTGACTTCGTTC
  SR15     5568      CACCTCTTTTGGTCTTCTCAG
  SR16     6010      CTTCCAGAGGCTGAGAGAAAGGCC
  SR17     6465      GAGTGTGAAAGCAACAAAACCC
Position 1 corresponds to the nucleotide A of the initiation codon of
the RHO gene.
1040patients and controls. Indel variation SV15 was also taken into
account, because it was found to be linked to SNP11. Table 5
shows 14 haplotypes consisting of eight major haplotypes and
six rare ones. The rare haplotypes (H09-H14) appeared to be
the result of a single conversion in the corresponding major
haplotype. There were five groups of LD structures of SNPs
and an Indel: SNP01-SNP02-SNP04-SNP14-SNP18, SNP06-
SNP09-SNP12-SNP13-SNP16, SNP07-SNP15, SNP08-
SNP10-SNP19, and SNP11-SV15. Eight major haplotypes can
produce 36 combinations, in which 29 were identified in 136
subjects. Seven major haplotypes, except for H08, were found
to exist as a homozygote. The most frequent haplotype, H01,
accounted for 27.2% of a total of 272 chromosomes. The
present comparison of haplotype frequencies did not reveal
any significant differences between RP patients and controls
when taking into account the multiple comparisons. With a
Bonferroni correction for the eight comparisons, a p-value of
0.05/8=0.006 is required for statistical significance.
Phylogeny of rhodopsin gene haplotypes: The phylogeny
of RHO haplotypes was calculated using the minimum span-
ning network algorithm (Figure 1). The area of the circle is
proportional to the frequency of each haplotype. The ratio of
RP patients (orange) and controls (light blue) for each haplo-
type is color-coded. The number of line segments between
circles corresponds to the number of nucleotide substitutions
between haplotypes. The graph in Figure 1 shows that the RHO
haplotypes can be classified into five groups separated by a
large number of nucleotide substitutions. The groups are des-
ignated as Group I to Group V. The haplotype-tagging SNP
(htSNP) distinguishing each group is described in the paren-
thesis following the group name in the Figure 1. Furthermore,
the htSNP distinguishing each haplotype in the group is de-
scribed in parenthesis following the haplotype name. These
htSNPs can be used as markers to estimate the haplotype of
new subjects.
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TABLE 4. NUCLEOTIDE SEQUENCE VARIATIONS OBSERVED IN THE RHODOPSIN GENE LOCUS
                                                                                  Minor allele frequency (%)
Marker     SNP                                        Alleles                     --------------------------
 name     name     Region    Amplicon   Position    major/minor       dbSNP ID     RP    Ctl    Sum    JSNP       JSNP ID
-------   -----   --------   --------   ---------   --------------   -----------  ----   ----   ----   -----   -------------
  SV01    SNP01   Upstream      A2       -1163           C/T         rs2625954    42.6   41.9   42.3    -            -
  SV02    SNP02   Upstream      A2        -778           A/C         rs2625955    41.9   41.9   41.9   42.0    IMS-JST108944
  SV03      -     Upstream      A2        -598           G/A              -        0.7    0.0    0.4    -            -
  SV04    SNP03    Exon 1     A2, A3       -51           G/A         rs2269736    33.8   28.7   31.3   33.2    IMS-JST024023
  SV05    SNP04    Exon 1     A2, A3       -26           G/A         rs7984       43.4   41.2   42.3   41.2    IMS-JST024024
  SV06      -      Exon 1     A2, A3       124      G/A(Ala42Thr)        -         0.0    0.7    0.4    -            -
  SV07      -      Exon 1       A3         273      C/T(Phe91Phe)        -         0.7    0.0    0.4    -            -
  SV08      -      Exon 1       A3         315      C/T(Phe105Phe)       -         0.7    0.0    0.4    -            -
  SV09    SNP05   Intron 1      A3         668           A/G             -         5.9    3.7    4.8    -            -
  SV10    SNP06   Intron 1      A3         709           C/T             -         5.9    5.1    5.5    -            -
  SV11      -     Intron 1      A3         794           G/A             -         0.0    0.7    0.4    -            -
  SV12      -     Intron 1      A3         966           C/T             -         0.7    0.0    0.4    -            -
  SV13    SNP07   Intron 1      A3        1349           T/G         rs2855552    29.4   30.1   29.8   28.3    IMS-JST130259
  SV14      -     Intron 1      A3        1354           C/T             -         1.5    1.5    1.5    -            -
   -        -     Intron 1      -         1535           G/A         rs2855553     -       -      -     -            -
  SV15      -     Intron 1      A3      1751-1760   AGGATGCATT/del       -        22.1   19.1   20.6    -            -
  SV16      -     Intron 1      A3      1775-1835   (CA)nA(CA)m          -         -       -      -     -            -
  SV17    SNP08   Intron 2      A4        2703           G/T         rs6803468     0.7    3.7    2.2    -            -
  SV18    SNP09   Intron 2      A4        2718           C/T             -         5.9    5.1    5.5    -            -
  SV19    SNP10   Intron 2      A4        2750           G/A         rs6803484     0.7    3.7    2.2    -            -
   -        -     Intron 2      -         2760           A/T         rs2855556     -       -      -     -            -
  SV20      -     Intron 2      A4        2753           A/G             -         0.0    0.7    0.4    -            -
  SV21      -     Intron 2      A4        2787           G/A             -         1.5    0.0    0.8    -            -
  SV22    SNP11   Intron 2      A4        2990           G/A             -        22.1   19.9   21.0    -            -
  SV23    SNP12   Intron 2      A4        3217           C/T             -         5.9    5.1    5.5    -            -
  SV24      -     Intron 2      A4        3269           C/T             -         0.7    0.0    0.4    -            -
  SV25      -     Intron 2      A4        3397           G/A             -         0.7    0.7    0.7    -            -
  SV26    SNP13   Intron 3      A4        3687           C/T             -         5.9    5.1    5.5    -            -
  SV27      -      Exon 4     A4, A5      3994      C/T(Ser297Ser)       -         1.5    1.5    1.5    -            -
  SV28      -     Intron 4    A4, A5      4056           G/T             -         1.5    0.0    0.8    -            -
  SV29    SNP14   Intron 4    A4, A5      4346           T/A         rs2855557    41.9   42.6   42.3    -            -
   -        -     Intron 4      -         4730           T/A         rs2625964     -       -      -     -            -
  SV30    SNP15   Intron 4      A5        4852           G/A         rs2071092    29.4   30.1   29.8   28.8    IMS-JST006396
  SV31    SNP16    Exon 5       A5        5028           C/A         rs2071093     5.9    5.1    5.5    4.3    IMS-JST006397
  SV32      -      Exon 5     A5, A6      5216           C/T             -         0.7    0.0    0.4    -            -
  SV33    SNP17    Exon 5     A5, A6      5217           G/A         rs2410       48.5   49.3   48.9    -            -
  SV34      -      Exon 5     A5, A6      5426           G/A             -         0.7    0.7    0.7    -            -
   -        -      Exon 5       -         5833           A/G         rs2625969     -       -      -     -            -
  SV35    SNP18    Exon 5     A5, A6      5897           G/A         rs2855558    41.9   41.9   41.9   42.5    IMS-JST086767
  SV36    SNP19    Exon 5     A5, A6      5910           T/C             -         0.7    2.9    1.8    -            -
  SV37      -      Exon 5     A5, A6      5914           C/T             -         0.0    0.7    0.4    -            -
  SV38      -      Exon 5       A6        5944           A/G             -         0.7    0.0    0.4    -            -
  SV39    SNP20    Exon 5       A6        6084           G/A         rs3733148     8.8   19.9   14.4   15.1    IMS-JST086768
  SV40      -      Exon 5       A6        6129           C/T             -         0.0    0.7    0.4    -            -
  SV41      -      Exon 5       A6        6193           G/A         rs3733149     0.0    0.7    0.4    0.8    IMS-JST086769
The amino acid substitution caused by nucleotide substitution was represented in parenthesis. Individual SNPs were characterized in 68
patients (RP) and 68 controls (Ctl). A database of Japanese single nucleotide polymorphisms (JSNP) contains nine SNPs that were measured
in 732-746 Japanese subjects.
1041DISCUSSION
 In this study, we did not detect any causative mutation in the
coding region of the RHO gene of 68 Japanese RP patients.
Five mutations in RHO have been reported to date for a total
of 85 Japanese adRP patients [16-19]; thus, the prevalence of
causative mutations in RHO is calculated to be 5.9%, sug-
gesting that RHO mutations may be among the common causes
of adRP in Japan. Based on the estimated number (at most 13)
of adRP patients in this study, the predicted number of cases
with a RHO mutation was less than 1. Thus, the present re-
sults are consistent with those of previous studies, indicating
that the rate of RHO mutations in Japanese adRP is low com-
pared to that of the American population. It should be noted
that more frequent occurrence of RHO mutations in the Ameri-
can patients is partially due to the presence of a large number
of families carrying Pro23His [27], which likely originated
from a single ancestor [28].
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TABLE 5. HAPLOTYPES OF THE JAPANESE RHODOPSIN GENE LOCUS
                                           SNP name                                   Number of chromosomes
Haplotype   --------------------------------------------------------------------   ---------------------------
  name      1  2  3  4  5  6  7   Indel    8  9 10 11 12 13 14 15 16 17 18 19 20   RP   Ctl    Sum   Frequency    χ2    p value
---------   -------------------   -----   --------------------------------------   --   ----   ---   ---------   ----   ------
   H01      T  C  G  A  A  C  T   Ins      G  C  G  G  C  C  A  G  C  A  A  T  G   45   29     74    0.272       4.75   0.029
   H02      C  A  A  G  A  C  T   Del      G  C  G  A  C  C  T  G  C  G  G  T  G   30   26     56    0.206       0.36   0.548
   H03      T  C  G  A  A  C  T   Ins      G  C  G  G  C  C  A  G  C  A  A  T  A   12   27     39    0.143       6.73   0.009
   H04      C  A  G  G  A  C  G   Ins      G  C  G  G  C  C  T  A  C  G  G  T  G   16   23     39    0.143       1.47   0.225
   H05      C  A  A  G  A  C  G   Ins      G  C  G  G  C  C  T  A  C  G  G  T  G   15   13     28    0.103       0.16   0.690
   H06      C  A  G  G  A  T  T   Ins      G  T  G  G  T  T  T  G  A  A  G  T  G    8    6     14    0.051       0.30   0.583
   H07      C  A  G  G  G  C  G   Ins      G  C  G  G  C  C  T  A  C  G  G  T  G    8    4     12    0.044       1.39   0.238
   H08      C  A  G  G  A  C  T   Ins      T  C  A  G  C  C  T  G  C  A  G  C  G    1    3      4    0.015       1.01   0.313
   H09      T  C  G  G  A  C  T   Ins      G  C  G  G  C  C  A  G  C  A  A  T  G    0    1      1    0.004
   H10      T  A  A  G  A  C  G   Ins      G  C  G  G  C  C  T  A  C  G  G  T  G    1    0      1    0.004
   H11      C  A  G  G  A  T  G   Ins      G  T  G  G  T  T  T  G  A  A  G  T  G    0    1      1    0.004
   H12      C  A  G  G  G  C  T   Ins      G  C  G  G  C  C  T  A  C  G  G  T  G    0    1      1    0.004
   H13      C  A  G  G  A  C  T   Ins      T  C  A  G  C  C  A  G  C  A  G  C  G    0    1      1    0.004
   H14      C  A  G  G  A  C  T   Ins      T  C  A  G  C  C  T  G  C  A  G  T  G    0    1      1    0.004
                                                                                   ---------   ---------------
                                                                            Total  136  136    272   1.000
A total of 136 subjects comprised of 68 retinitis pigmentosa patients (RP) and 68 controls (Ctr) were analyzed. One insertion/deletion (Indel)
variation was linked to SNP11. Red letters represent haplotype-tagging SNPs.
Figure 1. Phylogeny of Japanese rhodopsin gene haplotypes.  The area of the circle is proportional to the frequency of each haplotype. The
ratio of RP patients (orange) and controls (light blue) for each haplotype is color-coded. The number of line segments between circles corre-
sponds to the number of nucleotide substitutions between haplotypes. The RHO haplotypes can be classified into five groups designated as
Group I to Group V. The haplotype-tagging SNP (htSNP) distinguishing each group is described in the parentheses following the group name
and the haplotype name.
1042Unexpectedly, one novel heterozygous variation causative
of an amino acid substitution (Ala42Thr) was found in 1 con-
trol subject. This variation exists in the first transmembrane
domain. To date, eleven pathogenic variations have been re-
ported in the first transmembrane domain of RHO. The Ala
residue at position 42 is fairly conserved among vertebrate
opsins. Of 143 reported vertebrate opsin sequences, 130 have
an Ala at position 42, whereas 12 have Cys and 1 has Ser at
that position (GPCRDB: Information system for G protein-
coupled receptors (gpcr), release 10.0) [29]. The amino acid
change from a nonpolar Ala to a polar and slightly larger Thr
could affect the conformation of the first transmembrane do-
main. A similar substitution close to the 42nd Ala, Met44Thr,
has been reported in a patient with a simplex case of RP [30].
These findings suggest that Ala42Thr could be a pathogenic
mutation. However, the control subjects reported having no
symptoms such as night blindness or other visual impairments,
nor was there any family history of visual impairments. There
are three possibilities that might account for the discrepancy
between the predicted pathogenic phenotype and the appar-
ently silent phenotype of the carrier. The first possibility would
be that Ala42Thr is a rare benign variation. In fact, four non-
pathogenic missense changes have been reported thus far:
Thr70Met [9], Val104Ile [31], Pro220Leu [27], and Gly284Ser
[32]. On the other hand, a missense change, Glu150Lys, caused
recessive RP [12], and this second possibility suggests that
the Ala42Thr change might be a recessive mutation. The third
possibility would be that the symptoms were sufficiently mild
to escape the notice of the carrier. Unfortunately, this issue
remains unsolved, as we were unable to obtain any clinical
information on this subject.
Full sequencing of the RHO locus has revealed the pres-
ence of variations in the promoter region and introns. Seven
heterozygous variations occurred only in the RP patients: 1 in
the promoter region, 4 in the introns, and 2 in the 3'-UTR.
Although we cannot deny the possibility of causative muta-
tions, most cases may be rare variations. SV03 is located at
position -503 upstream of the transcription start site. This re-
gion did not show significant homology with the bovine RHO
promoter [33], and the corresponding bovine sequence was
not included in the protected regulatory elements determined
by DNase I footprint experiments [34]. We were also unable
to identify regulatory elements for retina-specific transcrip-
tion factors such as CRX, NRL, and NR2E3 [35] in this re-
gion. These results suggest that SV03 is unlikely to affect pro-
moter activity. This issue should be resolved in future experi-
ments by measuring the promoter activity of SV03 variants.
The fine mapping of SNPs has revealed eight haplotype
structures of the RHO locus in the Japanese population. The
haplotypes obtained are classified into five groups that may
stem from distinct Japanese ancestors. If a causative mutation
is associated with a specific haplotype, it may stem from a
single ancestor. From this perspective, it would be of interest
to determine which haplotypes carry frequent mutations such
as Pro23His and Pro347Leu [8].
Unfortunately, we were unable to identify RP-associated
SNPs or haplotypes. Our first expectation was that the haplo-
type of the promoter region may be associated with RP by
altering the levels of expression of RHO. The promoter re-
gion contains five SNPs (SNP01-SNP05) that construct four
haplotypes. Assessment of frequencies of these four haplotypes
did not reveal any significant differences between RP patients
and controls (data not shown), suggesting that there is no as-
sociation between susceptibility to RP and the RHO promoter
haplotype.
In conclusion, this was the first study to determine the
comprehensive sequence variations and haplotype structure
of the RHO locus, including the promoter region and introns.
No causative mutation in RHO was observed in 68 Japanese
patients with RP, but 1 control subject had a novel amino acid
substitution, Ala42Thr, which may have been benign. Although
we were unable to identify any RP-associated SNPs or
haplotypes, the htSNPs identified here will be useful as mark-
ers for the linkage-based screening of RP patients.
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